Asymchem has assembled a Board of Scientific Advisors (BSA) of 10 distinguished academic and industrial scientists with expertise in areas including enzyme evolution, asymmetric catalysis, and green chemistry. The advisory board will provide advice on high level strategic issues faced by Asymchem, and to assist in identification of new business opportunities.
Prof. Jin-Quan Yu
Professor of Scripps Institute, Fellow of the American Academy of Arts and Sciences, Professor of Chemistry of Frank and Bertha Hepp in 2012, and currently the leader of C-H bond activation research in international frontier disciplines. He obtained a bachelor degree from East China Normal University in 1987, a master degree in chemistry from Guangzhou Institute of Chemistry in 1990, a doctorate from Cambridge University in the United Kingdom in 1999 and entered Harvard University in 2000 for a two-year postdoctoral research. Professor Yu has successively served as an assistant professor in the Royal Society Research Institute at Cambridge University and Brandeis University, and as an associate professor at the Scripps Institute. He has published more than 200 high-quality papers, holds 26 patents, and won the 2017 Royal Chemical Society Pedler Award , 2016 MacArthur Genius Award, 2014 Elias J. Corey Award, 2012 ACS Arthur Science Scholar Award, 2009 China-US Association of Professors of Chemistry and Chemical Biology "Outstanding Professor Award", etc.
Prof. Phil Baran
Professor of the Scripps Institute, Fellow of the National Academy of Sciences of the US, Fellow of the American Academy of Sciences and the Arts, and one of the most famous young organic chemists nowadays.
He received a bachelor degree with honors from New York University in 1997, and a Ph.D. from the Scripps Institute in 2001. He then conducted a two-year postdoctoral study at Harvard University under the guidance of Professor E.J. Corey. Professor Baran has published more than 200 high-quality papers and has 15 core patents. He has won numerous honors and awards, such as the Inhoffen Medal in 2019, the ACS Elias J. Corey Award in 2016, the MacArthur Genius Award in 2013 and 2013 Royal Society of Chemistry Award for Organic Synthetic Chemistry. At the same time, Professor Baran is also a consultant for many large multinational companies, such as BMS (Bristol-Myers Squibb), DuPont (DuPont United States) and Boehringer-Ingelheim ( and so on.
Prof. Stephen L. Buchwald
Chief Professor of Chemistry at the Massachusetts Institute of Technology, Fellow of the American Academy of Arts and Sciences, and Fellow of the National Academy of Sciences. He has published 490 papers and 47 granted patents.
2000 Organic Metal Chemistry Award from American Chemical Society and MERIT Award from National Institutes of Health. He won the Bristol-Myers Squibb Award for Outstanding Achievement and CAS Science Focus Award in 2005, the Creative Work Award of the American Chemical Society for Synthetic Organic Chemistry, and the Siegfried Chemical Method Medal. Gustavus J. Esselen's 2010 Public Chemical Chemistry Award. 2013 Arthur C. Cope Award from the American Chemical Society. 2014 Linus Pauling Medal and Ulysses Medal (University of Dublin). He received an honorary doctorate from the University of South Florida in 2015 and also won the BBVA Basic Science Knowledge Award (2014 Award). Selected as the recipient of the 2016 William H. Nichols Medal and the 2018 Roger Adams Award for Organic Chemistry.
Prof. Nicholas Turner
Professor of the University of Manchester. He is one of the best experts in "making better enzymes" in the world, and has published nearly 40 papers.
Research fields: biocatalytic organic synthesis research; directed evolution of enzymes; protein process technology; design and synthesis of small molecule therapeutic protein inhibitors; development of biomass-to-biofuel technology.
Royal Society Wolfson Research Award (2011). RSC Organic Industrial Chemistry Award (2009); AZ / GSK / Prizer British Process Chemistry Research Award (2007); International Biocat Award (2004); Royal Society of Chemistry Cody-Morgan Medal and Winner (1996); Pfizer Organic Scholarship in Chemistry (1995); Carbohydrate Chemistry Medal of the Royal Society of Chemistry (1992); Royal Society Fullerton Gift and Binmore Kenner Junior Research Scholarship (1987).
Dr. Martin Eastgate
As the executive director of Bristol-Myers Squibb, Dr. Eastgate is experienced in scientific research and development and organizational leadership. With management of domestic teams and multinational teams, he is also responsible for BMS setting company product programs and developing disruptive innovation science.
Dr. Eastgate graduated from the University of Cambridge and worked with Dr. Stuart Warren on sulfur mediated, stereocontrolled, heterocycle synthesis; he had his post-doctoral research on Lewis-base mediated activation of Lewis-acids in collaboration with Professor Scott Denmark at the University of Illinois at Urbana-Champaign, The concept is applied in catalytic asymmetric transformation. He has published 70 papers and thesis, holds 9 patents and has won 8 awards, including Industrial Organic Chemistry Award, FRSC Fellow, International Society of Heterocyclic Chemistry Industrial Chemistry Award, Lecturer of McElvain, ACS Young Researcher, GlaxoSmithKline Postdoctoral Scholarship in Organic Chemistry, Syngenta Graduate Scholarship in Organic Chemistry, Margaret Evic Margaret Excellence Award in Organic Chemistry, etc.
Dr. Stephane Caron
As vice president of chemical process research and development of Pfizer, he is responsible for the discovery, development and commercialization of new drugs.
He obtained a master degree from Laval University in France in 1991 and a doctorate degree from the University of California, Berkeley in 1995. After that, he joined Pfizer in chemical process research and development. From the position of basic personnel in research and development to senior management, Dr. Caron has extensive experience in research and development and management. He has published more than 40 papers, 16 authorized patents, and holds positions in a number of international scientific organizations, such as: Member of the Canadian Natural Science and Engineering Technology Research Council 2003-2006, Member of the ACS Editor Selection Committee 2016, Organic Process Member of the editorial board of the Organic Process Research and Development journal.
Prof. Timothy F. Jamison
Associate Dean of Massachusetts Institute of Technology, Professor of Chemistry Robert R. Taylor, Co-founder, Chairman and Scientific Adviser of Snapdragon Chemistry, Member of the Royal Society of Chemistry.
He received his master degree from the University of California, Berkeley College in 1990 and his Ph.D. from Harvard University in 1997. Professor Jamison has published a number of core papers and books. He is also a member of the editorial board of the Journal of Flow Chemistry, a member of the Academic Advisory Board of the journal Advanced Synthesis and Catalysis, and Associate Editor of the Chemistry Review. Professor Jamison has won the 2011 Arthur Science Scholar Award from the American Chemical Society, the 2012 Merck Award from the Royal Society of Chemistry, the 2013 MIT Undergraduate Education Teaching Award, and the 2018 MIT Reformer Title IX Award.
Dr. Seble Wagaw
As the senior director of AbbVie Pharmaceuticals and head of organic synthesis and process development, she has 20 years of R & D and management experience at AbbVie.
Dr. Wagaw received a master degree from the University of Michigan in 1994 and a Ph.D. from the Massachusetts Institute of Technology in 1999. She then joined AbbVie, where she has extensive experience in R & D and management, from basic R & D staff to senior management. Dr. Wagaw is the co-founder of the AbbVie Women's Chemical Group, the co-founder of the Cross-industry Women's Chemical Process Group. She also won the 2013 ACS New Women's Award for Chemistry. At the same time, as a female elite in the industry, Dr. Wagaw was invited by various well-known universities and social organizations to deliver many professional lectures.
Dr. Scott A. May
Dr. May graduated from Hope College with a master degree in 1993. He graduated with a PhD in organic chemistry from Indiana University in 1998. He joined Eli Lilly's process R & D group as a senior organic chemist and is currently a researcher at RNA Therapeutics. Responsible for overall R & D and CMC work.
He has more than 20 years of experience in the synthesis design, material delivery and process development of new drug candidates, and has extensive experience from preclinical to advanced clinical trials. He has a strong capability of interdisciplinary collaboration in chemistry research discovery, analysis, formulations, regulations, quality and process engineering.
Expertise: synthetic organic chemistry, route selection, continuous processing, continuity, asymmetric catalysis, heterogeneous catalysis, route development, process enhancement, new technologies and regulations CMC, RNA Therapeutics, oligonucleotide synthesis, solid phase synthesis
Dr. Patricia A. Alred
President of Patricia Alred Consulting, specialist in market operations and biomolecular development. She has more than 20 years of extensive experience in research and development and commercial production, As a technical expert in both biotechnology development and production, she has extensive experience in clinical and commercial pharmaceutical product medical auditing and archiving; she also has a good understanding of lean culture.
Dr. Alred graduated with a PhD degree from Lund University, Sweden in 1993, and conducted post-doctoral research at the Massachusetts Institute of Technology from 1993 to 1995. Her research area is chemical engineering. She has worked in Bayer, Medlmmune, GlaxoSmithKline, Johnson & Johnson and other companies.
Involved areas: All aspects of biological R & D and commercial production, including medical and health GMP inspections of commercial products, and submission of new products BLA / MAA. She has developed standardized vision factories for pharmaceuticals, consumers and MD & D manufacturing, and conducted trials in 9 internal and external production sites and implemented them in Malvern.